Jul 24, 2026 · 6 min
Cloud growth boosts SAP while Sanofi dips on halted drug trial
SAP Beats, Sanofi Dips, Arcadis Gains
Understanding these corporate shifts reveals the divergent health of Europe's tech, pharmaceutical, and engineering sectors amid shifting demand and consolidation.
- 1SAP staged a major market rebound driven by strong cloud backlog growth and resilient software demand.
- 2Sanofi shares fell sharply after the pharmaceutical giant halted development on an experimental eczema treatment.
- 3Arcadis saw significant stock gains following a second unsolicited acquisition proposal from Canada's WSP Global.
The brief
European markets are seeing sharp divergence as corporate earnings season heats up. Breaking news editor Louise Moon joins the program to dissect the major corporate catalysts driving the latest stock market movements across Europe.
Software giant SAP led the region's positive momentum, staging a strong rebound. The company's growth was fueled by a significant surge in its cloud backlog, demonstrating resilient demand for cloud computing services despite broader macroeconomic headwinds.
In contrast, French pharmaceutical giant Sanofi faced a steep stock decline. The drop came after the company announced it is halting the development of a highly anticipated experimental eczema drug, dealing a blow to its pipeline.
Meanwhile, engineering and consulting firm Arcadis saw its shares jump. The company received a second unsolicited acquisition bid from Canada's WSP Global, signaling intense consolidation pressure and interest in global infrastructure consulting.
What was said on this episode
5 statements · 1 positive · 3 negative · 1 neutral
SAP still needs to catch up with competitors.
“analysts are saying they do still have some catching up to do against competitors”
Listen at 1:36
SAP’s strong cloud-product growth indicates improving prospects.
“this strong growth in that in cloud products is a good sign”
Listen at 1:42
Sanofi needs to expand its drug pipeline further.
“intensifies that need for that pipeline to be built out more”
Listen at 2:50
Sanofi’s pipeline weakness may increase pressure for more acquisitions.
“it also therefore potentially raises the pressure on her to pursue a more of an M and A approach”
Listen at 2:54
Arcadis previously rejected a lower acquisition offer.
“They previously rejected a lower offer.”
Listen at 3:26
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Mentioned
EuropeListen to the full episode and explore every guest, topic, and moment on PodLume.